WCI

Home > RI Related News > RI Related News

RI Related News

게시글 목록
No	TItle	Name	Date	Hit
815	Construction of China's First Domestic Medical Isotope Test Reactor Starts	WCI Secretariat	2024/03/11	696
814	Rosatom Building for Obninsk Radiopharmaceutical Plant Completed	WCI Secretariat	2024/03/11	660
813	Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform	WCI Secretariat	2024/03/11	653
812	Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177	WCI Secretariat	2024/03/11	642
811	AlphaGen Therapeutics and ARTBIO Announced Exclusive Strategic Collaboration for the Development and Commercialization of AB001 in Greater China and on ARTBIO’s 212Pb AlphaDirect™ Technology	WCI Secretariat	2024/03/11	702
810	Fusion Pharmaceuticals Enters Into Exclusive Worldwide License Agreement With Heidelberg University And Euratom For Actinium-Based PSMA Targeted Radiotherapy	WCI Secretariat	2024/03/11	642
809	PanTera Signed Agreement with Bayer for the Supply of Actinium-225	WCI Secretariat	2024/03/11	689
808	RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in Gastroenteropancreatic Neuroendocrine Tumors	WCI Secretariat	2024/03/11	645
807	Life Molecular Imaging and Oryx Isotopes Industrial Company announced a Strategic Partnership for the Production and Distribution of Florbetaben (18F) in the Kingdom of Saudi Arabia and Other Countries in Reach	WCI Secretariat	2024/03/11	662
806	ITM and Alpha-9 Oncology Announced Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program	WCI Secretariat	2024/03/11	685
805	Orano Med Lays Foundations for New Manufacturing Site for the Production of lead-212 Radioligand Therapies	WCI Secretariat	2024/03/11	700
804	Zeno Power Secures Radioisotope Fuel Supply from DOE to Build Full-Scale RPSs	WCI Secretariat	2024/03/11	719
803	First Targeted Alpha Therapy Wins FDA Breakthrough Device Designation RadioMedix and Orano Med’s Radioligand Therapy AlphaMedix (lead-212-Dotamtate) is currently in a Phase II trial	WCI Secretariat	2024/03/11	656
802	ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radio theranostics	WCI Secretariat	2024/01/08	855
801	Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses	WCI Secretariat	2024/01/08	835

First Prev 1 2 3 4 5 6 7 8 9 10 Next End (55 Page)

비밀글입니다!

글작성시 입력했던 비밀번호를 입력해주세요.